Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.
Marvell issues Google a $12.2 billion warrant for 59M shares in a multi-year partnership to develop custom AI chips for Google’s TPU ecosystem.
JPMorgan keeps Overweight rating and $21 target on Nokia, citing strong AI/cloud orders and IP network gains. Company also plans major China site closures.
TJX expects Q3 adjusted EPS of $1.30 to $1.32, below the $1.35 consensus, with comparable sales growth of 2% to 3% amid resilient off-price demand.
Shares fall in premarket on dilution fears as funds target AI data centers and GPUs.
Merck and Moderna’s personalized mRNA vaccine with Keytruda reduced melanoma recurrence in a 1,137-patient Phase 3 trial—the first late-stage win for an mRNA cancer vaccine.
